Following RYGB, the remission of T2D and improvement in metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals are affected differently by changes in FGF-19 and FGF-21. This evidence concerns the gene FGF19 and type 2 diabetes mellitus.